Certoparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Certoparin
Accession Number
DB09261
Type
Small Molecule
Groups
Approved, Investigational
Description

Certoparin is a low molecular weight heparin, primarily active against factor Xa. Like other low molecular weight heparins, it is used to prevent deep venous thrombosis.

Synonyms
Not Available
International/Other Brands
Embolex / Sandoparin
Categories
UNII
V72OT3K19I
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(1,2,6,7-3H)TestosteroneThe therapeutic efficacy of Certoparin can be increased when used in combination with (1,2,6,7-3H)Testosterone.
(R)-warfarinThe risk or severity of bleeding can be increased when Certoparin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Certoparin is combined with (S)-Warfarin.
1-TestosteroneThe therapeutic efficacy of Certoparin can be increased when used in combination with 1-Testosterone.
18-methyl-19-nortestosteroneThe therapeutic efficacy of Certoparin can be increased when used in combination with 18-methyl-19-nortestosterone.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Certoparin is combined with 4-hydroxycoumarin.
4-HydroxytestosteroneThe therapeutic efficacy of Certoparin can be increased when used in combination with 4-Hydroxytestosterone.
5beta-dihydrotestosteroneThe therapeutic efficacy of Certoparin can be increased when used in combination with 5beta-dihydrotestosterone.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Certoparin.
AcebutololThe risk or severity of hyperkalemia can be increased when Acebutolol is combined with Certoparin.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910425
Wikipedia
Certoparin_sodium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionRenal Dialysis1
3CompletedPreventionSystemic Embolism1
3CompletedPreventionThromboembolism1
3CompletedTreatmentPersistent Nonvalvular Atrial Fibrillation1
3TerminatedTreatmentNeoplasms / Venous Thromboembolism (VTE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 11:10 / Updated on November 02, 2018 07:00